Literature DB >> 17225944

Effects of systemic or topical administration of sodium selenite on early radiation effects in mouse oral mucosa.

Anja Gehrisch1, Wolfgang Dörr.   

Abstract

PURPOSE: To quantify the effect of sodium selenite (selenium) on radiation-induced oral mucositis (mouse) after subcutaneous or topical administration.
MATERIAL AND METHODS: Mucosal ulceration of the lower epithelium of mouse tongue was analyzed. Selenium (5 mug) was applied subcutaneously (s.c.) or locally, 60 min or 30 min prior to irradiation, respectively. In combination with single-dose irradiation, a single selenium application was given. With daily fractionated irradiation (3 Gy/fraction) for 1 week (days 0-4), selenium was administered at all 5 days of irradiation. With ten fractions over 2 weeks, selenium was applied in week 1, week 2, or both. All fractionation protocols were terminated by graded test doses to generate full dose-effect curves.
RESULTS: In a single-dose control experiment, the ED(50) (dose after which ulcer induction is expected in 50% of the mice) was 12.9 +/- 1.6 Gy. Selenium increased the ED(50) to 17.7 +/- 2.6 Gy (s.c.; p = 0.0003) and 16.3 +/- 3.0 Gy (local; p = 0.0104). The ED(50) for test irradiation after 5 x 3 Gy was 7.4 +/- 2.2 Gy. Subcutaneous administration of selenium resulted in an ED(50) of 11.5 +/- 2.0 Gy (p = 0.0015), local application yielded an ED(50) of 10.0 +/- 2.1 Gy (p = 0.0284). The ED(50) for test irradiation after 10 x 3 Gy/2 weeks was 8.0 +/- 1.7 Gy. Subcutaneous or local administration of selenium in week 1 yielded a significant increase in ED(50) to 10.5 +/- 1.0 Gy (p = 0.0069) and 10.7 +/- 1.0 Gy (p = 0.0039), respectively. By clear contrast, selenium administration in week 2 had no significant effect. Administration in both weeks resulted in an ED(50) of 9.1 +/- 2.0 Gy (s.c.; p = 0.2747) and 9.7 +/- 1.4 Gy (local; p = 0.0541).
CONCLUSION: Administration of sodium selenite during clinically relevant fractionated irradiation protocols has a significant effect during the initial treatment phase, i.e., week 1 in the mouse. Therefore, in clinical radiotherapy, the latent time to manifestation of confluent mucositis may be significantly prolonged, and hence the burden for the patient clearly reduced by selenium.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17225944     DOI: 10.1007/s00066-007-1594-4

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  12 in total

1.  Radiation protection following nuclear power accidents: a survey of putative mechanisms involved in the radioprotective actions of taurine during and after radiation exposure.

Authors:  Olav Albert Christophersen
Journal:  Microb Ecol Health Dis       Date:  2012-02-01

2.  Effects of bone marrow or mesenchymal stem cell transplantation on oral mucositis (mouse) induced by fractionated irradiation.

Authors:  M Schmidt; J Haagen; R Noack; A Siegemund; P Gabriel; W Dörr
Journal:  Strahlenther Onkol       Date:  2014-01-24       Impact factor: 3.621

Review 3.  [Radiation biology of normal tissues. Scientific progress and perspectives].

Authors:  W Dörr; C Herskind
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

4.  Dietary selenium for the mitigation of radiation injury: effects of selenium dose escalation and timing of supplementation.

Authors:  Fritz Sieber; Sarah A Muir; Eric P Cohen; Brian L Fish; Marylou Mäder; Ashley M Schock; Bryan J Althouse; John E Moulder
Journal:  Radiat Res       Date:  2011-07-08       Impact factor: 2.841

5.  8-prenylnaringenin and tamoxifen inhibit the shedding of irradiated epithelial cells and increase the latency period of radiation-induced oral mucositis : cell culture and murine model.

Authors:  Tine De Ryck; Annouchka Van Impe; Barbara W Vanhoecke; Arne Heyerick; Luc Vakaet; Wilfried De Neve; Doreen Müller; Margret Schmidt; Wolfgang Dörr; Marc E Bracke
Journal:  Strahlenther Onkol       Date:  2014-11-29       Impact factor: 3.621

6.  Non-small cell lung cancer in stages I-IIIB: Long-term results of definitive radiotherapy with doses ≥ 80 Gy in standard fractionation.

Authors:  Karl Wurstbauer; Hannes Weise; Heinz Deutschmann; Peter Kopp; Florian Merz; Michael Studnicka; Olaf Nairz; Felix Sedlmayer
Journal:  Strahlenther Onkol       Date:  2010-09-30       Impact factor: 3.621

Review 7.  Pharmacological modulators of the circadian clock as potential therapeutic drugs: focus on genotoxic/anticancer therapy.

Authors:  Marina P Antoch; Roman V Kondratov
Journal:  Handb Exp Pharmacol       Date:  2013

8.  Normal-tissue radioprotection by overexpression of the copper-zinc and manganese superoxide dismutase genes.

Authors:  Marlon R Veldwijk; Carsten Herskind; Leopold Sellner; Aleksandar Radujkovic; Stephanie Laufs; Stefan Fruehauf; W Jens Zeller; Frederik Wenz
Journal:  Strahlenther Onkol       Date:  2009-08-04       Impact factor: 3.621

9.  Selenium is a modulator of circadian clock that protects mice from the toxicity of a chemotherapeutic drug via upregulation of the core clock protein, BMAL1.

Authors:  Yan Hu; Mary L Spengler; Karen K Kuropatwinski; Maria Comas-Soberats; Marilyn Jackson; Mikhail V Chernov; Anatoly S Gleiberman; Natalia Fedtsova; Youcef M Rustum; Andrei V Gudkov; Marina P Antoch
Journal:  Oncotarget       Date:  2011-12

10.  Impact of treatment planning target volumen (PTV) size on radiation induced diarrhoea following selenium supplementation in gynecologic radiation oncology--a subgroup analysis of a multicenter, phase III trial.

Authors:  Ralph Muecke; Oliver Micke; Lutz Schomburg; Jens Buentzel; Michael Glatzel; Dieter Baaske; Regina Berndt-Skorka; Franz J Prott; Berthold Reichl; Klaus Kisters; Ulrich Schaefer; Jutta Huebner; Hans Th Eich; Guenther Kundt; Irenaeus A Adamietz
Journal:  Radiat Oncol       Date:  2013-03-25       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.